Aktuellt
SENASTE
The Prostatype Genomics Board has proposed a SEK 22.5m secured rights issue followed by SEK 22.5m in warrants at the same price as the initial right issue referring to attached warrants with a planned exercise period during Q1 2023. The total added growth capital is SEK 45m. This proposed rights issue is somewhat earlier than we expected in our recent initiation of cover.
LÄS MER
